Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

this threshold for at least 20 hours per week.

"We are pleased to report strong evidence supporting our hypothesis that administration of a threshold concentration of SNS-595 sustained over a defined period of time results in disease remissions in patients with acute leukemias," said Daniel C. Adelman, M.D., Sunesis' Senior Vice President, Research and Development. "Based on these recent data from our Phase 1 trial, a potential relationship between dose, pharmacodynamic target modulation and clinical response appears to be emerging which should allow us to select doses rationally for our planned Phase 2 clinical studies. With clinical responses observed to date in a study population with relapsed and/or refractory acute leukemias, we expect that SNS-595 will continue to show positive evidence of clinically meaningful activity as we escalate dosing in both treatment schedules to the MTD in this trial."

Dose escalation is in subsequent cohorts is continuing, with a 72 mg/m2 weekly dose cohort and a 50 mg/m2 twice-weekly cohort currently enrolling. Once the maximum tolerated dose (MTD) has been identified in each schedule, the study will enroll up to 10 additional patients at the MTD for each dosing regimen. Sunesis currently anticipates completing the clinical trial in time to report final results at the American Society of Hematology (ASH) meeting in Atlanta in December of this year.

SNS-595 is a replication-dependent DNA damaging agent that causes double- stranded DNA breaks, irreversible G2 arrest, and rapid apoptosis. The ongoing Phase 1 trial is being conducted by leading investigators at the H. Lee Moffitt Cancer Center & Research Institute, Johns Hopkins Hospital and the University of Texas, MD Anderson Cancer Center. The Phase 1 study is designed to assess the safety, tolerability and pharmacokinetics of SNS-595 and to establish a recommended Phase 2 dose for further testing among patients with acute leukemia. In addition, evidence fr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:8/31/2015)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), a global company engaged in the ... for the minimally invasive treatment of vascular disease, ... ("BTK") cohort of patients in the Chocolate® Balloon ... 15, 2015 at the 5th Annual Amputation Prevention ...
(Date:8/31/2015)... Aug. 31, 2015   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell ... cryopreservation freeze media and a related ... for smart shippers ("BioLife" or the ... an advanced biopharmaceutical company focused on developing and ...
(Date:8/30/2015)... GENEVA, Switzerland , August 31, 2015 ... join healthbank to ... healthbank , the world,s first citizen-owned health data transaction ... and Netcetera to engineer and bring ...      (Logo: http://photos.prnewswire.com/prnh/20150828/261966) , "Our business ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4
... IRVINE, Calif., Dec. 13, 2010 Masimo ... that a new clinical study demonstrating the accuracy of ... presented last week at the American Association of ... in Las Vegas. The largest gathering of respiratory care ...
... Texas, Dec. 13, 2010 Ascension Orthopedics, Inc., a ... implantation of the PyroTITAN™ Humeral Resurfacing Implant in France. ... from painful primary arthritis with synovial osteochondromotosis at Imperial ... first in continental Europe. The patient was discharged from ...
Cached Medicine Technology:New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 2New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 3New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 4New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 5New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 6Ascension Orthopedics Implants PyroTITAN™ in France 2
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo is pleased to ... Outdoor Sauna. After months of extensive engineering and design of our newest sauna model, ... the elements and is offered at a very attractive price-point. , Before outdoor ...
(Date:8/31/2015)... ... 31, 2015 , ... Wyoming Medical Center, an acute care ... Clinical Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural ... is an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing ...
(Date:8/31/2015)... ... , ... Castle Dermatology Institute now welcomes San Fernando Valley skin doctor ... the University of California, Los Angeles. He graduated summa cum laude with a Bachelor ... Medical School. As a nationally recognized Regents Scholar, Dr. Ghasri was given numerous honors ...
(Date:8/31/2015)... ... 2015 , ... “My mother and husband use oxygen therapy and the tubing ... there could be a comfortable way to prevent the irritation, so I invented this.” ... a more secure way to anchor the cannula tubing used in oxygen therapy and ...
Breaking Medicine News(10 mins):Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2
... 2008 South African scientists will gain access ... through an agreement announced today by the European ... Republic of South Africa signed a cooperation agreement ... intergovernmental funding body for EMBO, allowing scientists from ...
... to Rally Residents to Eat Right, Move More and ... Milk Their Diets, ... and downs of different fad diets -- which seem to go in and ... out of three Americans remain overweight or obese., A new campaign crossing ...
... System adds a smile to children, families traveling to and from ... ... Tenn., June 5 3-1-1 Travel,Bag, Inc., a developer of practical carry-on ... Bag,System toiletry cases for families traveling to and from St. Jude,Children,s Research ...
... Tufts University researcher Bess Dawson-Hughes, M.D., chaired ... Osteoporosis Foundation (NOF) Clinician,s Guide to Prevention ... Clinician,s Guide incorporates the World Health Organization ... computer-based tool expected to increase the identification ...
... Inc.,(Nasdaq: NUVO ) today announced the publication ... showing that the R-spondin family of,proteins activate the ... for,cell growth and differentiation during homeostasis and pathogenesis. ... proteins, and,modulated the Wnt pathway by a common ...
... N.J., June 5 Senesco,Technologies, Inc. ("Senesco" or ... details of its continuing preclinical multiple myeloma research. ... animal studies,in which Senesco,s Factor 5A technology, encapsulated ... myeloma tumors when injected,intratumorally., Senesco has continued ...
Cached Medicine News:Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:3-1-1 Travel Bag Donates to St. Jude Children's Research Hospital 2Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 2Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 3Health News:Senesco Expands on Preclinical Multiple Myeloma Findings 2Health News:Senesco Expands on Preclinical Multiple Myeloma Findings 3
... It is powerful, lightweight, ... comfortable, soft, durable foam ... pad, covered by machine ... Flexible headband easily adjusts ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Medicine Products: